Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Revenue of Celltrion, Inc. (068270.KS)
Revenue in 2023 (TTM): $1.5 B
According to Celltrion, Inc.'s latest financial reports the company's current revenue (TTM) is $1.5 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Celltrion, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.5 B | $696.57 M | $646.17 M | $462.42 M | $369.09 M |
| 2022 | $1.57 B | $711.58 M | $552.56 M | $431.47 M | $370.6 M |
| 2021 | $1.32 B | $761.95 M | $660.34 M | $517.69 M | $399.28 M |
| 2020 | $1.27 B | $708.12 M | $575.96 M | $452.81 M | $356.76 M |
| 2019 | $777.57 M | $436.51 M | $368.82 M | $263.24 M | $207.43 M |
| 2018 | $676.7 M | $379.61 M | $308.39 M | $207.85 M | $169.34 M |
| 2017 | $653.97 M | $480.85 M | $411.69 M | $332.86 M | $253.72 M |
| 2016 | $462.07 M | $273.28 M | $228.43 M | $158.02 M | $122.65 M |
| 2015 | $415.78 M | $254.15 M | $189.35 M | $112.39 M | $106.18 M |
| 2014 | $324.58 M | $235.06 M | $181.91 M | $102.75 M | $77.64 M |
| 2013 | $155.87 M | $108.54 M | $101.35 M | $79.7 M | $70.6 M |
| 2012 | $241.3 M | $176.59 M | $166.15 M | $129.24 M | $120.19 M |
| 2011 | $192.27 M | $156.27 M | $139.4 M | $126.36 M | $115.63 M |
| 2010 | $124.68 M | $97.51 M | $85.99 M | $75.7 M | $74.67 M |
| 2009 | $100.29 M | $64.74 M | $55.75 M | $45.76 M | $40.34 M |
| 2008 | $57.67 M | $32.77 M | $24.87 M | $12.14 M | $10.04 M |
| 2007 | $41.4 M | $6.36 M | $4.17 M | $184.15 K | $1.58 M |